# Treatment of Moderate to Severe Refractory Crohn's Disease

> **NCT06721962** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tr1X, Inc.** · enrollment: 39 (estimated)

## Conditions studied

- Crohns Disease

## Interventions

- **BIOLOGICAL:** TRX103
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06721962
- **Lead sponsor:** Tr1X, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-05
- **Primary completion:** 2026-01-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06721962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06721962, "Treatment of Moderate to Severe Refractory Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06721962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*